# Toward a Computationally-Informed, Personalized Treatment for Hallucinations

> **NCT04366518** · EARLY_PHASE1 · RECRUITING · sponsor: **Yale University** · enrollment: 35 (estimated)

## Conditions studied

- Hallucinations, Auditory
- Psychosis

## Interventions

- **DRUG:** Rivastigmine Transdermal System
- **DRUG:** Scopolamine
- **DRUG:** Placebo Patch
- **DRUG:** Placebo Patch

## Key facts

- **NCT ID:** NCT04366518
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-15
- **Primary completion:** 2032-08
- **Final completion:** 2032-08
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04366518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04366518, "Toward a Computationally-Informed, Personalized Treatment for Hallucinations". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT04366518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*